Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Young girls with turner syndrome proved by karyotype~* Growth hormone secretion confirmed with ornithin stimulation test~* Normal glucidic metabolism confirmed by assessment of HbA1c~* None associated severe pathology which could have impact on growth (i.e. renal insufficiency, decompensated heart failure)~* No previous or associated treatment with anabolic or sexual steroids~* Known parental height~Exclusion Criteria:~* Severe associated pathology with impact on growth~* Concomitant treatment with impact on growth~* Previous or associated treatment with anabolic steroids~* Associated growth hormone deficiency

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- r-hGH (Type: EXPERIMENTAL): Participants (girls) will receive r-hGH as a subcutaneous injection administered by a parent in the evening. During Years 1-2, the dose of r-hGH received will depend on participants' baseline height standard deviation score (SDS) relative to the general population standard: participants with a height SDS of -2 standard deviation (SD) or lower will receive 0.05 milligrams per kilogram (mg/kg) per day r-hGH and those with a height SDS between -1 and -2 SD will receive 0.035 mg/kg per day r-hGH. After 2 years of treatment, all participants will receive a fixed dose of 0.05 mg/kg per day for a further 2 years.
- Historical Control (Type: NO_INTERVENTION): This arm will include matching (age and height) historical control participants (girls) with turner syndrome, who were born between 1961 and 1990 and were untreated.

Based on this trial design, predict the completion outcome and termination type (if applicable).